SCHEMBL874259

SCHEMBL874259

C[C@@H](C(=O)OP(=O)(O)Cl)N(OCC(C)(C)C)c1cccc2ccccc12

nearest known ligand 0.34

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
HPGD P15428 2/20 0.33
THRB P10828 1/20 0.33
ADRB2 P07550 2/20 0.32
ADRB1 P08588 2/20 0.32
ADRB3 P13945 2/20 0.32
SIGMAR1 Q99720 2/20 0.32
KMT2A Q03164 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
SMPD2 O60906 1/20 0.32
KDM4E B2RXH2 3/20 0.32
HSD17B10 Q99714 1/20 0.32
ACP3 P15309 1/20 0.32
TDP1 Q9NUW8 1/20 0.31
PTK2B Q14289 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL472204 0.89 ALDH1A1 (0.36) ALDH1A1L3MBTL1HPGDTHRBSIGMAR1
SCHEMBL472185 0.87 SIGMAR1 (0.33) ALDH1A1L3MBTL1HPGDTHRBADRB2
SCHEMBL472191 0.86 ALDH1A1 (0.38) ALDH1A1L3MBTL1HPGDKMT2ASMPD2
SCHEMBL472186 0.85 SIGMAR1 (0.35) ALDH1A1L3MBTL1HPGDTHRBSIGMAR1
SCHEMBL873042 0.84 KDM4E (0.35) ALDH1A1L3MBTL1HPGDTHRBSIGMAR1
SCHEMBL22341535 0.78 ACP3 (0.39) KMT2AACP3
SCHEMBL874869 0.78 ACP3 (0.39) KMT2AACP3
SCHEMBL12496458 0.77 CTSG (0.39) ALDH1A1L3MBTL1HPGDKMT2ASMPD2
SCHEMBL1742656 0.76 KDM4E (0.37) ALDH1A1L3MBTL1HPGDKMT2AKDM4E
SCHEMBL12503918 0.74 SIGMAR1 (0.35) ALDH1A1HPGDSIGMAR1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250163096-A1 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS NuCana plc (GB) 2025-05-22 US disclosed
US-12054510-B2 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds NuCana plc (GB) 2024-08-06 US disclosed
US-20220306675-A1 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS NuCana plc (GB) 2022-09-29 US disclosed
US-11352387-B2 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds NuCana plc (GB) 2022-06-07 US disclosed
EP-3683225-A1 NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS Nucana PLC (GB) 2020-07-22 EP disclosed
US-20200181189-A1 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS NuCana plc (GB) 2020-06-11 US disclosed
US-10570168-B2 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compounds NuCana plc (GB) 2020-02-25 US disclosed
EP-3224268-B1 NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS NuCana plc (GB) 2019-06-26 EP disclosed
EP-3224268-A1 NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS NuCana BioMed Limited (GB) 2017-10-04 EP disclosed
US-20170253629-A1 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS NUCANA BIOMED LIMITED (GB) 2017-09-07 US disclosed
WO-2016083830-A1 NEW 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS NUCANA BIOMED LIMITED (GB) 2016-06-02 WO disclosed
WO-2012040126-A1 SUBSTITUTED NUCLEOTIDE ANALOGS ALIOS BIOPHARMA, INC. (US) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220306675-A1 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS MTAP, ADA, ADORA2A ALDH1A1 2246/4885L3MBTL1 725/4885HPGD 2829/4885
US-12054510-B2 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds MTAP, ADA, ADORA2A ALDH1A1 2198/4885L3MBTL1 741/4885HPGD 2814/4885
US-11352387-B2 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti-cancer compounds MTAP, RNMT, ADA ALDH1A1 2162/4885L3MBTL1 725/4885HPGD 2369/4885
US-10570168-B2 2′ and/or 5′ amino-acid ester phosphoramidate 3′-deoxy adenosine derivatives as anti- cancer compounds MTAP, RNMT, ADA ALDH1A1 2162/4885L3MBTL1 725/4885HPGD 2369/4885
US-20250163096-A1 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS MTAP, ADA, ADORA2A ALDH1A1 2246/4885L3MBTL1 725/4885HPGD 2829/4885
US-20200181189-A1 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS MTAP, ADA, RNMT ALDH1A1 2194/4885L3MBTL1 712/4885HPGD 2411/4885
US-20170253629-A1 2' AND/OR 5' AMINO-ACID ESTER PHOSPHORAMIDATE 3'-DEOXY ADENOSINE DERIVATIVES AS ANTI-CANCER COMPOUNDS MTAP, ADA, RNMT ALDH1A1 2194/4885L3MBTL1 712/4885HPGD 2411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.